Skip to content
A9055Assembly2023-2024 SessionSame asS7768

Cover Biologics and Biosimilars

Official title

“Relates to prescription drug formulary coverage for interchangeable biologics and biosimilars”

Sponsor John T. McDonald IIIAD-108+1 co-sponsorAffects Finance
Status
In Assembly Committee
Insurance
Impact
6/10
Moderate
Passage
0%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

This bill allows insurance plans to treat interchangeable biologics and biosimilars like generics for formulary and coverage purposes.

Why it matters

  1. Could lower costs for patients. By allowing insurers to treat interchangeable biologics and biosimilars like generics, patients may see reduced out-of-pocket costs for these often expensive medications, especially if these alternatives are placed on lower formulary tiers.

  2. Might speed up access to newer therapies. If biosimilars and interchangeable biologics are covered more favorably or more quickly, patients could gain access to effective alternatives sooner, rather than being restricted to brand-name biologics.

  3. Increases insurer flexibility in managing drug formularies. Insurers can move brand-name drugs to higher-cost tiers when an interchangeable or biosimilar is added, potentially driving market competition and encouraging use of more cost-effective treatments.

  4. Could impact provider prescribing and patient stability. The bill clarifies that even if a patient is stable on a current medication, insurers may require a trial of a generic, biosimilar, or interchangeable biologic before covering a brand-name drug, which could affect continuity of care for some patients.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Health insurers and utilization review agents

    The bill would allow required trials of interchangeable biologics or biosimilars before covering equivalent brand-name drugs, even when an insured is stable on prescribed treatment.

  • Patients stable on brand-name prescription drugs

    They could face a requirement to try an interchangeable biologic or biosimilar before receiving coverage for their existing drug.

  • Insurers with tiered drug formularies

    The bill would let them move a drug to a higher-cost-sharing tier when they simultaneously add a biosimilar to the formulary.

  • Biologic and biosimilar manufacturers

    The bill would expand insurers’ options to require trials of biologic alternatives and place competing drugs in higher-cost-sharing tiers when adding biosimilars.

Headline styles

Cover Biologics and Biosimilars

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
John T. McDonald III

Assembly Member · Assembly District 108

Chair, Governmental Operations

1 Co-sponsor

History

  1. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S7768Senate

Expand Drug Substitution Options

In Senate Committee · Insurance · Sponsor Michelle Hinchey

Impact 6 · Moderate0% to pass

Full text

1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

9055

IN ASSEMBLY

February 5, 2024

Introduced by M. of A. McDONALD -- read once and referred to the Committee on Insurance

AN ACT to amend the insurance law, in relation to prescription drug formulary coverage for interchangeable biologics and biosimilars

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Paragraph 4 of subsection (c-1) of section 4903 of the insurance law, as added by chapter 512 of the laws of 2016, is amended to read as follows:

(4) The insured is stable on a prescription drug or drugs selected by their health care professional for the medical condition under consideration, provided that this shall not prevent a utilization review agent from requiring an insured to try an AB-rated generic equivalent, an interchangeable biological product , or biosimilar prior to providing coverage for the equivalent brand name prescription drug or drugs; or

§ 2. Subparagraph (A) of paragraph 3 of subsection (c) of section 3242 of the insurance law, as added by chapter 99 of the laws of 2022, is amended to read as follows:

(A) An insurer with a formulary that includes two or more tiers of benefits providing for different deductibles, copayments or coinsurance applicable to prescription drugs in each tier may move a prescription drug to a tier with a larger deductible, copayment or coinsurance if an AB-rated generic equivalent [or], an interchangeable biological product, or biosimilar for such prescription drug is added to the formulary at the same time.

§ 3. Subparagraph (A) of paragraph 3 of subsection (c) of section 4329 of the insurance law, as added by chapter 99 of the laws of 2022, is amended to read as follows:

(A) A corporation with a formulary that includes two or more tiers of benefits providing for different deductibles, copayments or coinsurance applicable to prescription drugs in each tier may move a prescription drug to a tier with a larger deductible, copayment or coinsurance if an AB-rated generic equivalent [or], an interchangeable biological product, or biosimilar for such prescription drug is added to the formulary at the same time.

§ 4. This act shall take effect immediately.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD11861-01-3

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.